KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Capital Employed (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Return on Capital Employed for 8 consecutive years, with 0.53% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed fell 13.0% year-over-year to 0.53%, compared with a TTM value of 0.53% through Dec 2025, down 13.0%, and an annual FY2025 reading of 0.58%, down 132.0% over the prior year.
  • Return on Capital Employed was 0.53% for Q4 2025 at Esperion Therapeutics, down from 8.44% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 8.44% in Q3 2025 and bottomed at 2.71% in Q4 2023.
  • Average Return on Capital Employed over 5 years is 0.33%, with a median of 0.86% recorded in 2022.
  • The sharpest move saw Return on Capital Employed plummeted -176bps in 2023, then surged 834bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.99% in 2021, then increased by 3bps to 0.95% in 2022, then plummeted by -184bps to 2.71% in 2023, then soared by 124bps to 0.66% in 2024, then dropped by -20bps to 0.53% in 2025.
  • Business Quant data shows Return on Capital Employed for ESPR at 0.53% in Q4 2025, 8.44% in Q3 2025, and 0.96% in Q2 2025.